<ul>
<li><strong>Cerapro® 是一种获得专利的皮肤 pH 值降低霜，已根据欧洲医疗器械法规（CE 标志）批准用于治疗特应性皮炎。</strong></li>
<li><strong>产品计划于 2026 年在包括瑞士、奥地利、荷兰和比利时在内的六个欧洲市场推出。</strong></li>
</ul>
<p>, /PRNewswire/ -- Hyphens Pharma International Limited（&#34; <strong>Hyphens Pharma</strong>&#34;，或称&#34; <strong>公司</strong>&#34;，与其子公司合称为&#34; <strong>集团</strong>&#34;），新加坡领先的专业制药和消费者医疗保健集团，欣然宣布已授予 Louis Widmer SA（&#34; <strong>Louis Widmer</strong>&#34;）商业化其创新产品 Cerapro® MED 皮肤屏障霜的权利，签署了一项涵盖瑞士、列支敦士登、奥地利、比利时、卢森堡和荷兰六个欧洲国家的许可、供应和商业化协议（&#34; <strong>外部许可协议</strong>&#34;）。</p>
<p>根据与 Louis Widmer 的外部许可协议，Hyphens Pharma 将获得一次性费用和销售的常规版税。</p>
<p>特应性皮炎是一种常见的湿疹形式，影响各个年龄段的数百万人。皮肤 pH 值升高和皮肤屏障功能受损是导致这种皮肤状况的主要因素。Cerapro®凭借其专利配方，降低皮肤 pH 值并帮助恢复皮肤屏障。作为根据严格的欧洲医疗器械法规（MDR）获得 CE 标志的医疗器械，Cerapro®为湿疹患者提供了一种新颖的治疗选择。降低皮肤 pH 值也支持皮肤固有的抗微生物防御系统。</p>
<p>在此次合作中，Louis Widmer 是一家总部位于瑞士的国际化妆品和制药公司，自 1960 年以来以高质量的皮肤病产品而闻名，将在约定市场中商业化和推广 Cerapro®给皮肤科医生和儿科医生。这一合作反映了两家公司共同的愿景，即提供以科学为基础的产品，以改善患者的治疗效果。</p>
<p>&#34; <em>与 Louis Widmer 的这一里程碑式合作伙伴关系彰显了我们对创新和患者护理的承诺，</em>&#34; Hyphens Pharma 董事长兼首席执行官 Lim See Wah 表示。<em>&#34;通过利用 Louis Widmer 在皮肤科的强大影响力和专业知识，我们旨在将 Cerapro®带给欧洲的患者，同时继续探索新的增长机会。</em>&#34;</p>
<p>&#34; <em>我们很高兴与 Hyphens Pharma 合作，将 Cerapro®引入我们的市场，为患者提供经过临床验证的特应性皮炎解决方案。</em> <em>Cerapro®将成为我们 Remederm 系列的新旗舰，该系列在欧洲的专业零售商和医生中都是干燥、非常干燥和特应性皮肤护理的领导者。</em> _&#34; Louis Widmer 的首席执行官 Annemarie Widmer 说道。</p>
<p><strong>关于 Hyphens Pharma International Limited</strong></p>
<p>Hyphens Pharma International Limited 及其子公司（&#34;集团&#34;）是新加坡领先的专业制药和消费者医疗保健集团，秉持着每个人都应享有更好生活质量的信念。</p>
<p>集团总部位于新加坡，在马来西亚、越南、印度尼西亚和菲律宾设有直接业务，并在泰国、柬埔寨、文莱、孟加拉国、缅甸、香港特别行政区和阿曼等地拓展业务。其五个主要实体——Hyphens Pharma、DocMed Technology、Ocean Health、Novem 和 Ardence Aesthetics，共同推进三个核心业务领域：制药与医疗美容、专有品牌以及数字平台与电子药房。</p>
<p>除了通过与全球品牌主要公司的独家合作伙伴关系在选定的东盟市场营销和分销专业制药产品外，集团还开发和商业化专有的皮肤病和健康补充产品。集团的综合生态系统扩展到医疗超市和数字药房平台，实现无缝的处方履行和直接向患者的药物配送，为医疗保健提供者提供便利。</p>
<p>更多信息请访问 www.hyphensgroup.com。</p>
<p><strong>关于 Louis Widmer SA</strong></p>
<p>Louis Widmer SA 是一家来自瑞士的国际化妆品和制药公司。这家家族企业总部位于苏黎世附近，以其高质量的护肤和皮肤病产品而闻名。自 1960 年成立以来，Louis Widmer 致力于可持续发展和创新。</p>
<p>他们通过开发、生产和分销药品和皮肤药妆产品而脱颖而出。其主要专业领域包括干燥皮肤、痤疮、色素障碍、伤口愈合、抗衰老和防晒等多个方面。</p>
<p>更多信息请访问 www.louis-widmer。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>代表发布</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>媒体咨询请联系</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>邮箱 / DID / 手机</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
<p><em>本媒体发布已由公司的赞助商 SAC Capital Private Limited（&#34;赞助商&#34;）审核。它未经过新加坡交易所证券交易有限公司（&#34;SGX-ST&#34;）的审查或批准，SGX-ST 对本媒体发布的内容不承担任何责任，包括对本媒体发布中所作的任何声明或意见的正确性。</em></p>
<p><em>赞助商的联系人是 Ms Lee Khai Yinn（电话：（65）6232 3210），地址：新加坡罗宾逊路 1 号，#21-01 AIA 大厦，邮政编码 048542。</em></p>
<p>来源 Hyphens Pharma International Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy"/></p>

凯帆药剂国际

<p>凯帆药剂国际已将其 Cerapro® MED 皮肤屏障霜授权给 Louis Widmer SA，在包括瑞士和比利时在内的六个欧洲国家进行商业化。该产品已获得 CE 标志认证，作为治疗特应性皮炎的医疗器械，计划于 2026 年上市。凯帆药剂将获得预付款和销售提成。此次合作旨在利用 Louis Widmer 在皮肤病学方面的专业知识，以改善欧洲患者的治疗效果</p>

<ul>
<li><strong>Cerapro® is a patented, skin pH-lowering cream approved for the treatment of atopic dermatitis under the European</strong> <strong>Medical Device Regulation (</strong> <strong>CE Mark)</strong></li>
<li><strong>Product launch targeted for 2026 in six European markets, including Switzerland, Austria, the Netherlands and Belgium.</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Cerapro® 是一种获得专利的皮肤 pH 值降低霜，已根据欧洲医疗器械法规（CE 标志）批准用于治疗特应性皮炎。</strong></li>
<li><strong>产品计划于 2026 年在包括瑞士、奥地利、荷兰和比利时在内的六个欧洲市场推出。</strong></li>
</ul>
</div><p>, /PRNewswire/ -- Hyphens Pharma International Limited (&#34; <strong>Hyphens Pharma</strong>&#34;, or the &#34; <strong>Company</strong>&#34;, and together with its subsidiaries, the &#34; <strong>Group</strong>&#34;), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA (&#34; <strong>Louis Widmer</strong>&#34;) via a licensing, supply and commercialisation agreement (&#34; <strong>Out-Licensing Agreement</strong>&#34;) that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Hyphens Pharma International Limited（&#34; <strong>Hyphens Pharma</strong>&#34;，或称&#34; <strong>公司</strong>&#34;，与其子公司合称为&#34; <strong>集团</strong>&#34;），新加坡领先的专业制药和消费者医疗保健集团，欣然宣布已授予 Louis Widmer SA（&#34; <strong>Louis Widmer</strong>&#34;）商业化其创新产品 Cerapro® MED 皮肤屏障霜的权利，签署了一项涵盖瑞士、列支敦士登、奥地利、比利时、卢森堡和荷兰六个欧洲国家的许可、供应和商业化协议（&#34; <strong>外部许可协议</strong>&#34;）。</p>
</div><p>In accordance with the Out-Licensing Agreement with Louis Widmer, Hyphens Pharma will receive an upfront fee and customary royalties on sales.</p>
<div class="lb-trans"><p>根据与 Louis Widmer 的外部许可协议，Hyphens Pharma 将获得一次性费用和销售的常规版税。</p>
</div><p>Atopic dermatitis, a common form of eczema, affects millions across all age groups. Elevated skin pH and impaired skin barrier function are key drivers of this skin condition. Cerapro®, with its patented formulation, lowers skin pH and helps restore the skin barrier. Approved as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), Cerapro® offers a novel treatment option for patients with eczema. Lowering skin pH also supports the skin's inherent antimicrobial defence system.</p>
<div class="lb-trans"><p>特应性皮炎是一种常见的湿疹形式，影响各个年龄段的数百万人。皮肤 pH 值升高和皮肤屏障功能受损是导致这种皮肤状况的主要因素。Cerapro®凭借其专利配方，降低皮肤 pH 值并帮助恢复皮肤屏障。作为根据严格的欧洲医疗器械法规（MDR）获得 CE 标志的医疗器械，Cerapro®为湿疹患者提供了一种新颖的治疗选择。降低皮肤 pH 值也支持皮肤固有的抗微生物防御系统。</p>
</div><p>Under this collaboration, Louis Widmer, a Swiss-based international cosmetics and pharmaceuticals company renowned for high-quality dermatology products since 1960, will commercialise and promote Cerapro® to dermatologists and paediatricians in the agreed markets. This collaboration reflects the shared vision of both companies to deliver science-backed products that enhance patient outcomes.</p>
<div class="lb-trans"><p>在此次合作中，Louis Widmer 是一家总部位于瑞士的国际化妆品和制药公司，自 1960 年以来以高质量的皮肤病产品而闻名，将在约定市场中商业化和推广 Cerapro®给皮肤科医生和儿科医生。这一合作反映了两家公司共同的愿景，即提供以科学为基础的产品，以改善患者的治疗效果。</p>
</div><p>&#34; <em>This milestone partnership with Louis Widmer underscores our commitment to innovation and patient care,&#34;</em> said Mr Lim See Wah, Chairman and CEO of Hyphens Pharma. <em>&#34;By leveraging Louis Widmer's strong presence and expertise in dermatology, we aim to bring Cerapro® to patients in Europe while continuing to explore new growth opportunities.&#34;</em></p>
<div class="lb-trans"><p>&#34; <em>与 Louis Widmer 的这一里程碑式合作伙伴关系彰显了我们对创新和患者护理的承诺，</em>&#34; Hyphens Pharma 董事长兼首席执行官 Lim See Wah 表示。<em>&#34;通过利用 Louis Widmer 在皮肤科的强大影响力和专业知识，我们旨在将 Cerapro®带给欧洲的患者，同时继续探索新的增长机会。</em>&#34;</p>
</div><p>&#34; <em>We are excited to partner with Hyphens Pharma to introduce Cerapro® to our markets, offering patients a clinically proven solution for atopic dermatitis.</em> <em>Cerapro® will be the new flagship of our Remederm line, which is a leader in Europe in both specialist retailers and doctors for the care of dry, very dry and atopic skin.</em> <em>,</em>&#34; said Ms Annemarie Widmer, CEO of Louis Widmer.</p>
<div class="lb-trans"><p>&#34; <em>我们很高兴与 Hyphens Pharma 合作，将 Cerapro®引入我们的市场，为患者提供经过临床验证的特应性皮炎解决方案。</em> <em>Cerapro®将成为我们 Remederm 系列的新旗舰，该系列在欧洲的专业零售商和医生中都是干燥、非常干燥和特应性皮肤护理的领导者。</em> _&#34; Louis Widmer 的首席执行官 Annemarie Widmer 说道。</p>
</div><p><strong>About Hyphens Pharma International Limited</strong></p>
<div class="lb-trans"><p><strong>关于 Hyphens Pharma International Limited</strong></p>
</div><p>Hyphens Pharma International Limited and its subsidiaries (the &#34;Group&#34;) is Singapore's leading specialty pharmaceutical and consumer healthcare group, driven by the belief that everyone deserves access to a better quality of life.</p>
<div class="lb-trans"><p>Hyphens Pharma International Limited 及其子公司（&#34;集团&#34;）是新加坡领先的专业制药和消费者医疗保健集团，秉持着每个人都应享有更好生活质量的信念。</p>
</div><p>From its headquarters in Singapore, it maintains a direct presence in Malaysia, Vietnam, Indonesia and the Philippines, with extended reach into Thailand, Cambodia, Brunei, Bangladesh, Myanmar, Hong Kong S.A.R. and Oman. Its five key entities — Hyphens Pharma, DocMed Technology, Ocean Health, Novem, and Ardence Aesthetics, collectively advance three core business areas: Pharmaceuticals &amp; Medical Aesthetics, Proprietary Brands, and Digital Platform &amp; E-Pharmacy.</p>
<div class="lb-trans"><p>集团总部位于新加坡，在马来西亚、越南、印度尼西亚和菲律宾设有直接业务，并在泰国、柬埔寨、文莱、孟加拉国、缅甸、香港特别行政区和阿曼等地拓展业务。其五个主要实体——Hyphens Pharma、DocMed Technology、Ocean Health、Novem 和 Ardence Aesthetics，共同推进三个核心业务领域：制药与医疗美容、专有品牌以及数字平台与电子药房。</p>
</div><p>Beyond marketing and distributing specialty pharmaceutical products across selected ASEAN markets through exclusive partnerships with global brand principals, the Group develops and commercialises proprietary dermatological and health supplement products. The Group's integrated ecosystem extends to a medical hypermart and digital pharmacy platform, enabling seamless prescription fulfillment and direct-to-patient medication delivery for healthcare providers.</p>
<div class="lb-trans"><p>除了通过与全球品牌主要公司的独家合作伙伴关系在选定的东盟市场营销和分销专业制药产品外，集团还开发和商业化专有的皮肤病和健康补充产品。集团的综合生态系统扩展到医疗超市和数字药房平台，实现无缝的处方履行和直接向患者的药物配送，为医疗保健提供者提供便利。</p>
</div><p>More information is available at www.hyphensgroup.com.</p>
<div class="lb-trans"><p>更多信息请访问 www.hyphensgroup.com。</p>
</div><p><strong>About Louis Widmer SA</strong></p>
<div class="lb-trans"><p><strong>关于 Louis Widmer SA</strong></p>
</div><p>Louis Widmer SA is an international cosmetics and pharmaceuticals company from Switzerland. The family company, with its head office near Zurich, is known for its high-quality skin care and dermatology products. Since it was founded in 1960, Louis Widmer has dedicated itself to sustainability and innovation.</p>
<div class="lb-trans"><p>Louis Widmer SA 是一家来自瑞士的国际化妆品和制药公司。这家家族企业总部位于苏黎世附近，以其高质量的护肤和皮肤病产品而闻名。自 1960 年成立以来，Louis Widmer 致力于可持续发展和创新。</p>
</div><p>They distinguish themselves by developing, producing, and distributing both pharmaceutical and dermocosmetic products. Their main areas of expertise include dry skin, acne, pigmentation disorders, wound healing, anti-aging, and sun protection, among many others.</p>
<div class="lb-trans"><p>他们通过开发、生产和分销药品和皮肤药妆产品而脱颖而出。其主要专业领域包括干燥皮肤、痤疮、色素障碍、伤口愈合、抗衰老和防晒等多个方面。</p>
</div><p>More information is available at www.louis-widmer.</p>
<div class="lb-trans"><p>更多信息请访问 www.louis-widmer。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Issued on behalf of</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>For media enquires contact</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>Email / DID / Mobile</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>代表发布</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>媒体咨询请联系</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>邮箱 / DID / 手机</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
</div><p><em>This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the &#34;Sponsor&#34;). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the &#34;SGX-ST&#34;) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.</em></p>
<div class="lb-trans"><p><em>本媒体发布已由公司的赞助商 SAC Capital Private Limited（&#34;赞助商&#34;）审核。它未经过新加坡交易所证券交易有限公司（&#34;SGX-ST&#34;）的审查或批准，SGX-ST 对本媒体发布的内容不承担任何责任，包括对本媒体发布中所作的任何声明或意见的正确性。</em></p>
</div><p><em>The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.</em></p>
<div class="lb-trans"><p><em>赞助商的联系人是 Ms Lee Khai Yinn（电话：（65）6232 3210），地址：新加坡罗宾逊路 1 号，#21-01 AIA 大厦，邮政编码 048542。</em></p>
</div><p>SOURCE Hyphens Pharma International Limited</p>
<div class="lb-trans"><p>来源 Hyphens Pharma International Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN56002&amp;Transmission_Id=202601050430PR_NEWS_USPR_____CN56002&amp;DateId=20260105"/></p>

凯帆药剂国际将 Cerapro® MED 皮肤屏障霜的许可授权给六个欧洲国家